SCHEMBL208188

SCHEMBL208188

Clc1ccc2n[c]ccc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.38
F3 P13726 1/20 0.38
DYRK1A Q13627 1/20 0.38
PIK3CG P48736 2/20 0.37
CYP2A6 P11509 1/20 0.37
HTR3A P46098 3/20 0.37
HRH4 Q9H3N8 1/20 0.37
ALDH1A1 P00352 2/20 0.36
BACE1 P56817 2/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207987 0.83 NR4A2 (0.47) F7F3DYRK1APIK3CGCYP2A6
SCHEMBL2718077 0.77 MAPK13 (0.34) DYRK1AALDH1A1KDM4EGLAPOLB
SCHEMBL208135 0.75 BACE1 (0.47) CYP2A6ALDH1A1BACE1KDM4ENR4A2
SCHEMBL206393 0.75 BACE1 (0.47) CYP2A6ALDH1A1BACE1KDM4ENPSR1
SCHEMBL7630593 0.75 KDM4E (0.52) DYRK1AHTR3AALDH1A1KDM4EPOLB
SCHEMBL407633 0.75 CYP1A2 (0.55) CYP2A6ALDH1A1BACE1KDM4E
SCHEMBL207952 0.72 EGFR (0.31)
SCHEMBL5748489 0.71 CYP1A2 (0.42) CYP2A6ALDH1A1KDM4EPOLBGAA
SCHEMBL5748279 0.71 CYP2A6 (0.38) CYP2A6ALDH1A1KDM4EPOLBGAA
SCHEMBL1826613 0.71 HRH3 (0.38) DYRK1ACYP2A6ALDH1A1KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111201245-B Compounds, compositions, and methods 戴纳立制药公司 2024-04-05 CN claimed
CN-111094233-B Compounds, compositions, and methods 戴纳立制药公司 2024-03-15 CN claimed
EP-4248965-A2 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2023-09-27 EP claimed
EP-3676297-B1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2023-05-17 EP claimed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 US claimed
US-20200331900-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2020-10-22 US claimed
EP-3676297-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-07-08 EP claimed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 EP claimed
CN-111094233-A Compounds, compositions and methods 戴纳立制药公司 2020-05-01 CN claimed
WO-2019046779-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2019-03-07 WO claimed
US-20040180884-A1 Dibenzocycloheptene compound UBE INDUSTRIES, LTD. (JP) 2004-09-16 US claimed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 US claimed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP claimed
EP-1408033-A1 DIBENZOCYCLOHEPTENE COMPOUND Ube Industries, Ltd. (JP) 2004-04-14 EP claimed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP claimed
US-20030216571-A1 Antiallergens; antiinflammatory agents UBE INDUSTRIES, LTD. (JP) 2003-11-20 US claimed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 EP claimed
EP-1254897-A1 TRICYCLIC COMPOUNDS Ube Industries, Ltd. (JP) 2002-11-06 EP claimed
US-5624937-A TREATMENT OF ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1997-04-29 US claimed
US-5378711-A α-arylacrylates substituted by a heterocyclic radical, and fungicides which contain these compounds BASF AKTIENGESELLSCHAFT (DE) 1995-01-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331900-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E F7 2108/4885F3 2049/4885DYRK1A 3936/4885
US-20040180884-A1 Dibenzocycloheptene compound LTB4R2, LTA4H, LTC4S F7 2444/4885F3 1285/4885DYRK1A 2752/4885
US-20030216571-A1 Antiallergens; antiinflammatory agents CYSLTR2, CYSLTR1, LTC4S F7 2277/4885F3 1311/4885DYRK1A 3034/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E F7 2005/4885F3 1986/4885DYRK1A 3904/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 F7 491/4885F3 57/4885DYRK1A 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.